stockrowGRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. 10-Q filed Nov 5, 2026
Red flags
-
Short cash runway
GRAIL, Inc.’s cash and short-term investments cover about 0.4 quarters of its operating cash burn
-
Share dilution
Shares outstanding rose 15.3% in a year, to 45.0 million
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 9 added · 6 removed · 35 modified; 10 with only figures updated; 1 moved without change
-
Modified
You should read the following discussion of our results of operations and financial condition together with our accompanying unaudited condensed consolidated financial statements and the notes thereto included under Item 1. “Financial Statements”. This discussion contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and our business and financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in the sections entitled “Risk Factors” in Part II, Item 1A of this Form 10-Q and in Part I, Item 1A of our Annual Report on Form 10-K (filed on March 12, 2026) for the year ended December 31, 2025 (the “2025 Form 10-K”) and the section entitled “Cautionary
StatementNote Concerning Forward-Looking Statements” of this Form 10-Q.